Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BTP-114 in Advanced Solid Tumors
NCT02950064Phase 1Unknown
- Sponsor
- Placon Therapeutics
- Start
- Sep 2016
- Primary completion
- Apr 2020
- Modality
- DNA Intercalators/Alkylators, Prodrugs/Conditional Activator Small Molecules, Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of BTP-114 in solid tumor (advanced stage), pancreatic cancer (PC), ovarian cancer and 2 more, sponsored by Placon Therapeutics. Primary endpoints: Maximum Tolerated Dose at 52 weeks, Recommended Phase 2 Dose at 52 weeks and 5 more. Status: unknown.
02
Drugs
BTP-114
03
Conditions
solid tumor (advanced stage)pancreatic cancer (PC)ovarian cancertriple-negative breast cancer (TNBC)castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on NCT02950064.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02950064.